• HUGE : CSE • FSDDF : OTC • FSDDF: OTCQB
FSD’s R&D platform focuses on cannabinoids and their potential for widespread clinical applications. With the acquisition of Prismic Pharmaceuticals, they have added an R&D platform with the capability of producing synthetic cannabinoids and opioid sparing compounds that would hopefully gain FDA approval to commercialize prescription medications in United States, Canada & ROW.
PROCESSING & MANUFACTURING
PHARMA RESEARCH & DEVELOPMENT
The Fundamentals of FSD Pharma are Strong:
No long term debt
Non-cash assets over $72 M
Raised $4.5M at a premium ($20.10 a share) with a major investment infusion by the CEO, Dr. Raza Bokhari, of $1.5M USD
FSD Pharma Receives Cannabis Sales License from Health Canada
Copyright © 2019. All rights reserved.